ipraalox 20 mg zarnās šķīstošās tabletes
opella healthcare france s.a.s., france - pantoprazols - zarnās šķīstošā tablete - 20 mg
actifed 60 mg/2,5 mg tabletes
mcneil healthcare (ireland) limited, ireland - triprolidini hydrochloridum, pseudoephedrini hydrochloridum - tablete - 60 mg/2,5 mg
montelukast accord 10 mg apvalkotās tabletes
accord healthcare b.v., netherlands - montelukasts - apvalkotā tablete - 10 mg
finasteride accord 1 mg apvalkotās tabletes
accord healthcare b.v., netherlands - finasterīds - apvalkotā tablete - 1 mg
montelukast accord 5 mg košļājamās tabletes
accord healthcare b.v., netherlands - montelukasts - košļājamā tablete - 5 mg
montelukast accord 4 mg košļājamās tabletes
accord healthcare b.v., netherlands - montelukasts - košļājamā tablete - 4 mg
regaine 50 mg/ml uz ādas lietojams šķīdums
mcneil healthcare (ireland) limited, ireland - minoksidils - uz ādas lietojams šķīdums - 50 mg/ml
valganciclovir accord 450 mg apvalkotās tabletes
accord healthcare b.v., netherlands - valganciklovīrs - apvalkotā tablete - 450 mg
zercepac
accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastiski līdzekļi - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. pirms ķīmijterapijas ir jāietver vismaz anthracycline un taxane, ja vien pacientiem ir derīgi šiem apstrādes veidiem. hormonu receptoru pozitīvu pacientiem jābūt arī neizdevās hormonu terapiju, ja vien pacientiem ir derīgi šiem apstrādes veidiem. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. kopā ar docetaxel par attieksmi pret pacientiem, kuri nav saņēmuši ķīmijterapiju to metastātiska slimība. kombinācijā ar aromatāzes inhibitoru, lai ārstētu menopauzes pacientiem ar hormonu receptoru pozitīvu mbc, kas agrāk nav ārstēti ar trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). pēc operācijas, ķīmijterapija (neoadjuvant vai palīgvielas) un staru terapijas laikā (ja piemērojams). šādas palīgvielas ķīmijterapija ar doksorubicīna un ciklofosfamīdu, kopā ar paclitaxel vai docetaxel. kopā ar palīgvielu ķīmijterapiju, kas sastāv no docetaxel un carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. precīza un apstiprinātas pārbaudes metodes vajadzētu izmantot,.
pregabalin accord
accord healthcare s.l.u. - pregabalin - anxiety disorders; epilepsy - antiepileptics, - epilepsypregabalin accord ir norādīts kā adjunctive terapija pieaugušajiem ar daļēju lēkmju ar vai bez sekundāras vispārināšanas. Ģeneralizēta trauksme disorderpregabalin accord ir indicēts, lai ārstētu Ģeneralizēta trauksme (vsd) pieaugušajiem.